Iron Absorption From a Nutritional Iron Supplement
Conventional oral iron supplements often cause gastrointestinal side effects and are limited by poor bioavailability, leaving unabsorbed iron to reach the colon. Hydrocolloid-based hydrogel matrix formulations designed for gradual iron release present a promising approach to improve iron absorption. This study evaluates fractional iron absorption (FIA) from three low-dose hydrogel formulations containing ferrous fumarate compared with ferrous fumarate without a hydrogel matrix. Test products will be administered with water, with and without a standardized breakfast. All formulations will be intrinsically labelled with stable iron isotopes ( 57Fe or 54Fe), and FIA will be determined 14 days after administration based on erythrocyte iron incorporation. In this randomized, within-subject corssover study conducted in non-anemic, iron-depleted women, each participant will receive all test conditions and serve as her own control.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Suplemento dietético: Iron-Enriched Hydrogel Supplement (A with breakfast)
- Suplemento dietético: Iron-Enriched Hydrogel Supplement (B with breakfast)
- Suplemento dietético: Iron-Enriched Hydrogel Supplement (A without breakfast)
- Suplemento dietético: Iron-Enriched Hydrogel Supplement (B without breakfast)
- Suplemento dietético: Iron-Enriched Hydrogel Supplement (C with breakfast)
- Suplemento dietético: Control (FeFum, with breakfast)
- Suplemento dietético: Control (FeFum, without breakfast)
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Camarena
- Número de telefone: +41446328393
- E-mail: seline.camarena@pharma.ethz.ch
Locais de estudo
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Suíça, 8006
- Recrutamento
- ETH Zürich, Laboratory of Clinical Biopharmacy
-
Contato:
- Camarena
- Número de telefone: +41446328393
- E-mail: seline.camarena@pharma.ethz.ch
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Female aged 18 to 45 years
- Plasma ferritin <30 µg/L
- Body mass index (BMI) 18.5 kg/m2 - 24.9 kg/m2.
- Body weight <65 kg.
- Signed informed consent
- Sufficient command of English (mother tongue or B2 level)
Exclusion Criteria:
- Anemia, defined as hemoglobin (Hb) <120 g/L (<12.0 g/dL).
- Elevated systemic inflammatory markers (C-reactive protein >5.0 mg/L).
- Chronic digestive, renal and/or metabolic diseases
- Chronic medications (except for contraceptives)
- Use of vitamin, mineral, or pre-/Pprobiotic supplements in the 2 weeks before or during the study
- Blood transfusion, blood donation or significant blood loss (>400ml) over the past 4 months
- Difficulty with blood withdrawal
- Pregnancy (tested in serum/urine) or intention to become pregnant during the course of the study
- Lactation
- Previous participation in a study using stable isotopes or participation in any clinical study within the last 30 days
- Participants who cannot be expected to comply with the study protocol (e.g. not available on certain study appointments)
- Inability to understand the information sheet and the informed consent form due to cognitive or language reasons
- Smoking (>1 cigarette/week)
- Vegan diet (the standardized breakfast contains plain whole milk yogurt and butter)
Special exclusion criteria for participants in the MRI imaging sub-study (n=9):
- Presence of a heart pacemaker, neurostimulator, or any other active implanted electronic device.
- Use of a hearing aid that cannot be safely removed for the MRI examination.
- Use of removable dentures that cannot be safely removed for the MRI examination.
- History of surgery on the head or heart involving implanted material that is not confirmed MRI-safe.
- Presence of metallic objects in the body (e.g. implants, magnets, metal splinters, gunshot fragments, tattoos, piercings, or surgical clips) that are not confirmed MRI-safe.
- History of metal splinter injury (e.g. ocular foreign body) or occupational exposure associated with increased risk of retained metal fragments.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: FeHydro-A with breakfast (Condition 1)
FeHydro-A with sodium ascorbate, consumed with a standardized breakfast |
FeHydro-A (20 mg elemental iron as ferrous fumarate embedded in hydrogel matrix; labeled with 57Fe or 54Fe) + Standardized Breakfast
Outros nomes:
|
|
Experimental: FeHydro-B with breakfast (Condition 2)
FeHydro-B without sodium ascorbate, consumed with a standardized breakfast |
FeHydro-B (20 mg elemental iron as ferrous fumarate embedded in hydrogel matrix; labeled with 57Fe or 54Fe) + Standardized Breakfast
Outros nomes:
|
|
Experimental: FeHydro-A without breakfast (Condition 3)
FeHydro-A with sodium ascorbate, consumed without breakfast |
FeHydro-A (20 mg elemental iron as ferrous fumarate embedded in hydrogel matrix; labeled with 57Fe or 54Fe) + 300 mL Water |
|
Experimental: FeHydro-B without breakfast (Condition 4)
FeHydro-B without sodium ascorbate, consumed without breakfast |
FeHydro-B (20 mg elemental iron as ferrous fumarate embedded in hydrogel matrix; labeled with 57Fe or 54Fe) + 300 mL Water |
|
Experimental: FeHydro-C with breakfast (Condition 5)
FeHydro-C with sodium ascorbate and gum arabic, consumed with a standardized breakfast |
FeHydro-C (20 mg elemental iron as ferrous fumarate embedded in hydrogel matrix; labeled with 57Fe or 54Fe) + Standardized Breakfast |
|
Comparador Ativo: Control with breakfast (Condition 6)
Control ferrous fumarate, consumed with a standardized breakfast |
Control (20 mg elemental iron as ferrous fumarate without hydrogel matrix, in gelatin capsule; labeled with 57Fe or 54Fe) + Standardized Breakfast |
|
Comparador Ativo: Control without breakfast (Condition 7)
Control ferrous fumarate, consumed without breakfast |
Control (20 mg elemental iron as ferrous fumarate without hydrogel matrix, in gelatin capsule; labeled with 57Fe or 54Fe) + 300 mL Water |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fractional Iron Absorption
Prazo: 14 days after administration of each labelled test condition
|
Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in red blood cells |
14 days after administration of each labelled test condition
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRONH
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data (IPD) will not be made publicly available to protect participant privacy and maintain confidentiality regarding proprietary formulation data. De-identified, aggregated study results and primary outcome data will be published in peer-reviewed scientific journals and made available via public study registries upon completion of the trial.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .